In patients with ALT levels > 30 U/L, obesity, type-2 DM, dyslipidemia, hypertension, or steatotic liver disease, along with a platelet count ≤ 200,000 or FIB-4 index ≥ 1.3 is used to predict advanced fibrosis [3], and consultation with a gastroenterologist and hepatologist is recommended. This evidence concerns the gene GPT and liver disorder.